Theranos Would Be Thriving in the Covid-19 Pandemic
Relaxed regulations, misinformation, and a big potential payout are reminiscent of the conditions that cultivated Theranos
In November 2015, the U.S. House of Representatives held a hearing about draft guidance from the U.S. Food and Drug Administration (FDA) about closing a regulatory loophole…